Fig. 22.1 Advancement through different phases in clinical trials Clinical trial design for oncology studies can broadly be categorized into rule-based and model-based designs. Rule-based designs are often used in…
Fig. 17.1 (a) Kaplan-Meier survival plots for baseline DCE-MRI parameters in breast cancer patients scheduled to undergo neoadjuvant chemotherapy. Left: overall survival plot for the relative signal enhancement at 30…
Fig. 16.1 A wound response signature of genes differentially expressed between tissue from reduction mammoplasty and histologically normal tissue of cancer patients. The dendrogram in cancer-adjacent normal samples (red) and…
Fig. 2.1 Phenotypic and molecular heterogeneity of endothelium at different metastatic sites. Although the endothelium is a common barrier encountered by tumor cells at all metastatic sites, tissue-specific heterogeneity means…
Fig. 21.1 Nodular malignant melanoma . Cutaneous melanoma of the nodular subtype. Please note the red halo around the lesion representing an inflammatory immune response against neo-antigens present in the…
Fig. 12.1 Mechanisms of platelet activation. Under normal, physiological conditions, platelets rapidly form a clot upon contact with a site of vascular damage (a). Damage to the endothelium leads to…
, Yaping Hua1, 2, Karl-Henning Kalland1, 2 , Xisong Ke1, 2, Jan Roger Olsen1, 2, Anne Margrete Øyan1, 2 and Yi Qu1, 2 (1) Department of Clinical Science, University of Bergen, Bergen, Norway (2) Department of Microbiology, Haukeland University…
Fig. 11.1 Schematic overview of human diseases associated with the presence of TLS Ectopic Lymphoid Tissue in Autoimmunity and Infectious Diseases In chronic inflammatory diseases, TLS arise at sites of…
Fig. 20.1 Shown are H/E stainings of astrocytomas , WHO grade II–IV as indicated. Grade II astrocytoma displays a slight hypercellularity and moderate cellular pleomorphism. Grade III, or anaplastic astrocytoma,…
Characteristic NRP1 NRP2 Chromosome location 10p11.22 (human) 2q33.3 (human) Molecular weight 130–140 kDa 130–140 kDa Receptor isoforms NRP1, NRP1Δ16 NRP2a17, NRP2a22 NRP2b0, NRP2b5 Soluble forms s11NRP1, s12NRP1, sIIINRP1, sIVNRP1, s10Nrp1…
